articleNature MedicineJan 6, 2013Closed access

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

AJAndrew J. SouersJDJoel D. LeversonERErwin R. BoghaertSAScott AcklerNDNathaniel D. Catron

AbbVie (United States) · The University of Melbourne · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

3,009
total citations
FWCI
106.84
Percentile
100%
References
48
Citations per year

Authors

40

Topics & keywords

Topics
Keywords
  • Chronic lymphocytic leukemia
  • Cancer research
  • Apoptosis
  • Venetoclax
  • In vivo
  • Bcl-2 family
  • Lymphoma
  • Leukemia
No related works found for this paper.